| SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 P Chen, A Nirula, B Heller, RL Gottlieb, J Boscia, J Morris, G Huhn, ... New England Journal of Medicine 384 (3), 229-237, 2021 | 1436 | 2021 |
| Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial RL Gottlieb, A Nirula, P Chen, J Boscia, B Heller, J Morris, G Huhn, ... Jama 325 (7), 632-644, 2021 | 1019 | 2021 |
| Phase 3 studies comparing brodalumab with ustekinumab in psoriasis M Lebwohl, B Strober, A Menter, K Gordon, J Weglowska, L Puig, K Papp, ... New England Journal of Medicine 373 (14), 1318-1328, 2015 | 845 | 2015 |
| Bamlanivimab plus etesevimab in mild or moderate Covid-19 M Dougan, A Nirula, M Azizad, B Mocherla, RL Gottlieb, P Chen, C Hebert, ... New England Journal of Medicine 385 (15), 1382-1392, 2021 | 664 | 2021 |
| A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis KA Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, ... British Journal of Dermatology 175 (2), 273-286, 2016 | 477 | 2016 |
| Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis PJ Mease, MC Genovese, MW Greenwald, CT Ritchlin, AD Beaulieu, ... New England Journal of Medicine 370 (24), 2295-2306, 2014 | 463 | 2014 |
| What is IgG4? A review of the biology of a unique immunoglobulin subtype A Nirula, SM Glaser, SL Kalled, FR Taylora Current opinion in rheumatology 23 (1), 119-124, 2011 | 425 | 2011 |
| Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients J Stebbing, V Krishnan, S de Bono, S Ottaviani, G Casalini, ... EMBO molecular medicine 12 (8), e12697, 2020 | 287 | 2020 |
| Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial MS Cohen, A Nirula, MJ Mulligan, RM Novak, M Marovich, C Yen, ... Jama 326 (1), 46-55, 2021 | 205 | 2021 |
| Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19 JT Sims, V Krishnan, CY Chang, SM Engle, G Casalini, GH Rodgers, ... Journal of Allergy and Clinical Immunology 147 (1), 107-111, 2021 | 167 | 2021 |
| Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment K Papp, C Leonardi, A Menter, EHZ Thompson, CE Milmont, G Kricorian, ... Journal of the American Academy of Dermatology 71 (6), 1183-1190. e3, 2014 | 137 | 2014 |
| Hybrid DNA artifact from PCR of closely related target sequences. AR Shuldiner, A Nirula, J Roth Nucleic acids research 17 (11), 4409, 1989 | 134 | 1989 |
| Clinical meaningfulness of complete skin clearance in psoriasis B Strober, KA Papp, M Lebwohl, K Reich, C Paul, A Blauvelt, KB Gordon, ... Journal of the American Academy of Dermatology 75 (1), 77-82. e7, 2016 | 114 | 2016 |
| Biomarker profiles in asthma with high vs low airway reversibility and poor disease control WW Busse, ST Holgate, SW Wenzel, P Klekotka, Y Chon, JY Feng, ... Chest 148 (6), 1489-1496, 2015 | 80 | 2015 |
| Distinct regions in the CD28 cytoplasmic domain are required for T helper type 2 differentiation PG Andres, KC Howland, A Nirula, LP Kane, L Barron, D Dresnek, ... Nature immunology 5 (4), 435-442, 2004 | 78 | 2004 |
| Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19 M Dougan, M Azizad, P Chen, B Feldman, M Frieman, A Igbinadolor, ... MedRxiv, 2022.03. 10.22272100, 2022 | 77 | 2022 |
| Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis K Papp, A Menter, B Strober, G Kricorian, EHZ Thompson, CE Milmont, ... Journal of the American Academy of Dermatology 72 (3), 436-439. e1, 2015 | 65 | 2015 |
| Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases A Nirula, J Nilsen, P Klekotka, G Kricorian, N Erondu, JE Towne, ... Rheumatology 55 (suppl_2), ii43-ii55, 2016 | 64 | 2016 |
| A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of … M Dougan, M Azizad, B Mocherla, RL Gottlieb, P Chen, C Hebert, R Perry, ... Clinical Infectious Diseases 75 (1), e440-e449, 2022 | 62 | 2022 |
| Transcription factor AP‐2 activates gene expression of HTLV‐I. C Muchardt, JS Seeler, A Nirula, S Gong, R Gaynor The EMBO Journal 11 (7), 2573-2581, 1992 | 61 | 1992 |
